Barclays PLC Buys 23,738 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE)

Barclays PLC lifted its stake in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 361.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,306 shares of the company’s stock after buying an additional 23,738 shares during the period. Barclays PLC’s holdings in Pulse Biosciences were worth $530,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PLSE. State Street Corp increased its holdings in Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after purchasing an additional 69,696 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after purchasing an additional 97,565 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after buying an additional 9,639 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Pulse Biosciences in the 3rd quarter valued at approximately $588,000. Finally, Rhumbline Advisers boosted its position in Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after buying an additional 1,608 shares during the period. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Stock Up 2.2 %

Shares of NASDAQ:PLSE opened at $17.79 on Friday. Pulse Biosciences, Inc. has a 12-month low of $6.59 and a 12-month high of $22.69. The business has a fifty day simple moving average of $18.02 and a 200 day simple moving average of $16.90.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period in the prior year, the business earned ($0.19) earnings per share.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, CEO Burke Thomas Barrett sold 50,000 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at approximately $1,100,456.24. The trade was a 44.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert W. Duggan purchased 56,054 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were acquired at an average price of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the acquisition, the director now directly owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 71.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research report on Thursday.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.